DKFZ-HIPO Data Access Committee of Heidelberg Center for Personalized Oncology

Request Access

This DAC controls 202 datasets

Dataset ID	Description	Technology	Samples
EGAD00001000366	WGBS data of whole blood samples from smoking and non-smoking mothers and their children at gestation/birth and follow-up years.	Illumina HiSeq 2000	52
EGAD00001000884	In order to elucidate whether newly acquired genetic alterations during serial transplantation of patient derived primary pancreatic cancer cultures contribute to the observed clonal dynamics in vivo, all coding genes of two patient derived primary cultures and derived genetically marked serial xenografts (1°/2°/3°) were sequenced.	Illumina HiSeq 2000	10
EGAD00001000992	HIPO blastemal Wilms (nephroblastoma) characterisation of tumor driving events caused by differential SIX1 binding of the SIX1 Q177R mutatns	Illumina HiSeq 2500	3
EGAD00001000993	HIPO blastemal Wilms (nephroblastoma) characterisation of tumor driving gene expression events	Illumina HiSeq 2000	40
EGAD00001000994	HIPO blastemal Wilms (nephroblastoma) characterisation of tumor driving chromosomal aberrations	Illumina HiSeq 2000 Illumina HiSeq 2500	56
EGAD00001000995	HIPO blastemal Wilms (nephroblastoma) characterisation of tumor driving DNA alterations	Illumina HiSeq 2000	112
EGAD00001000997	Whole-exome sequencing of a chronic lymphocytic leukemia (CLL) developed during vemurafenib treatment of a patient with malignant melanoma. Peripheral blood mononuclear cells were separated by Ficoll gradient centrifugation. DNA was extracted from highly purified (>97%) CD19+CD5+ cells obtained from the patient while being under BRAF inhibition versus CD14+ germline control cells (>90% purity). No alterations that could be linked to aberrant RAS activity or paradoxical RAF/MEK/ERK signaling could be identified in the CLL, which shows characteristic copy number alterations.	Illumina HiSeq 2500	2
EGAD00001001384	Mutations that activate the RAF-MEK-ERK signaling pathway, in particular BRAFV600E, occur in many cancers, and mutant BRAF-selective inhibitors have clinical activity in these diseases. Activating BRAF alleles are usually considered to be mutually exclusive with mutant RAS, whereas inactivating mutations in the D594F595G596 motif of the BRAF activation segment can coexist with oncogenic RAS and cooperate via paradoxical MEK/ERK activation. We determined the functional consequences of a largely uncharacterized BRAF mutation, F595L, which was detected along with an HRASQ61R allele by clinical exome sequencing in a patient with histiocytic sarcoma and also occurs in epithelial cancers, melanoma, and neuroblastoma, and investigated its interaction with mutant RAS. We demonstrate that, unlike previously described DFG motif mutants, BRAFF595L is a gain-of-function variant with intermediate activity towards MEK that does not act paradoxically, but nevertheless cooperates with mutant RAS to promote oncogenic signaling. Of immediate clinical relevance, BRAFF595L shows divergent responses to different mutant BRAF-selective inhibitors, whereas signaling driven by BRAFF595L with and without mutant RAS is efficiently blocked by pan-RAF and MEK inhibitors. Mutation data from primary patient samples and cell lines show that BRAFF595L, as well as other BRAF mutations with intermediate activity, frequently coincide with mutant RAS in a broad spectrum of cancers. These data define a novel class of activating BRAF mutations that cooperate with oncogenic RAS in a non-paradoxical fashion to achieve an optimal level of MEK-ERK signaling, extend the spectrum of patients with systemic histiocytic disorders and other malignancies who are candidates for therapeutic blockade of the RAF-MEK-ERK pathway, and underscore the value of comprehensive genetic profiling for understanding the signaling requirements of individual cancers.	Illumina HiSeq 2500	2
EGAD00001001444	Atypical teratoid/rhabdoid tumor (ATRT) is one of the most common brain tumors in infants and young children. Although the prognosis of ATRT patients is poor, some patients respond very well to current treatments, suggesting inter-tumor molecular heterogeneity. To investigate this further, we genetically and epigenetically analyzed a large cohort of ATRTs (n = 170). Three distinct molecular subgroups of ATRTs, associated with differences in demographics, tumor location and type of SMARCB1 alterations, were identified using DNA-methylation or gene expression analyses. Whole genome DNA- and RNA-sequencing found no other recurrent mutations explaining the differences between subgroups. However, whole genome bisulfite-sequencing and H3K27Ac ChIP-sequencing of primary tumors revealed clear differences in methylation patterns and enhancer landscapes, leading to the identification of subgroup-specific regulatory networks.	Illumina HiSeq 2000 Illumina HiSeq 2500	55
EGAD00001002011	RNA sequencing data of whole blood samples from smoking and non-smoking mothers and their children at gestation/birth and follow-up years.		64
EGAD00001002012	ChIPseq data of whole blood samples from smoking and non-smoking mothers and their children at gestation/birth and follow-up years.		16
EGAD00001002055	Whole exome sequencing from matched tumor-control samples of 121 primary lymphoma samples. Sequencing was performed on Illumina HiSeq2000. The dataset contains FASTQ files.	Illumina HiSeq 2000	242
EGAD00001002056	Paired-end RNA sequencing using total RNA from 136 primary lymphoma samples. Sequencing was performed on the Illumina HiSeq2000 with 300bp insert size. The dataset contains FASTQ files.	Illumina HiSeq 2000	136
EGAD00001002135	ChIPseq data of Atypical teratoid/rhabdoid tumors (ATRT)	Illumina HiSeq 2000 Illumina HiSeq 2500	15
EGAD00001002136	RNA sequencing data of Atypical teratoid/rhabdoid tumors (ATRT)	Illumina HiSeq 2000	25
EGAD00001002137	WGBS data of Atypical teratoid/rhabdoid tumors (ATRT)	Illumina HiSeq 2000 Illumina HiSeq 2500	15
EGAD00001002138	WGS data of Atypical teratoid/rhabdoid tumors (ATRT)	Illumina HiSeq 2000	36
EGAD00001002159	Exome Seq for Study EGAS00001001844	Illumina HiSeq 2000	2
EGAD00001002160	Exome Seq for EGAS00001001845	Illumina HiSeq 2500	2
EGAD00001002161	Transcriptome from EGAS00001001845	Illumina HiSeq 2500	1
EGAD00001002162	Exome Seq from EGAS00001001846	Illumina HiSeq 2500	2
EGAD00001002163	Transcriptome from EGAS00001001846	Illumina HiSeq 2500	1
EGAD00001002164	Exome from EGA00001001848	Illumina HiSeq 2000	2
EGAD00001002166	Exome from EGAS00001001861	Illumina HiSeq 2000	17
EGAD00001002528	WGS from EGAS00001001857	Illumina HiSeq 2000	18
EGAD00001003325	Exome from EGAS00001002441	Illumina HiSeq 2500	2
EGAD00001003408	Chip-Seq sequencing data of Atypical teratoid/rhabdoid tumors (ATRT)	Illumina HiSeq 2000	19
EGAD00001003421	Sequence data of 28 Samples (19 chronic lymphocytic leukemia, 9 control) Including RNA-Seq and ChIP-Seq of following histone modifications: H3, H3K4me1, H3K4me3, H3K9ac, H3K9me3, H3K27ac, H3K27me3, H3K36me3 Project see: http://www.cancerepisys.org/		28
EGAD00001003827	The data set contains bam files aligned using bwa-0.7.8 mem -t 8 -R.	HiSeq X Ten	4
EGAD00001003828	This dataset contains paired fastq files for LMS tumor samples	Illumina HiSeq 2000 Illumina HiSeq 2500	37
EGAD00001003829	The data set contains paired end fastq files for whole exome sequencing data for Leiomyosarcoma tumor and control samples	Illumina HiSeq 2000 Illumina HiSeq 2500	96
EGAD00001003965	Whole genome sequencing of Control (blood), Tumor and metastasis triplets for 12 samples.	Illumina HiSeq 2000	36
EGAD00001004068	Whole-genome, whole-exome and transcriptome sequencing of pancreatic ductal adenocarcinomas from young adults reveals recurrent NRG1-fusions in KRAS wild-type tumors.	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	36
EGAD00001004563	This dataset contains whole genome sequencing data from 21 primary and relapsed IDH-wt glioblastomas and matched blood controls. Tumors were sequenced at a target coverage of 150x, blood controls at 80x.	HiSeq X Ten	63
EGAD00001004564	This dataset contains strand-specific RNA sequencing data from 16 primary/relapsed sample pairs of IDH-wt glioblastomas	Illumina HiSeq 2000	32
EGAD00001004565	This dataset contains gene panel sequencing data from 43 sample pairs of primary and relapsed IDH-wt glioblastomas. The gene panel covers 50 glioma-associated genes. 14 of the sequenced sample pairs were sequenced with whole genome sequencing also and are accessible under EGAD00001004563.	Ion Torrent Proton	86
EGAD00001004825	Case series of the rare tumor entity chordoma. 9 cases sequenced with Whole Exome Sequencing (WES) and 2 cases sequenced with Whole Genome Sequencing (WGS) were recruited from the personalized oncology program NCT-MASTER/DKTK-MASTER at the German Cancer Research Center. One of the WES patients was re-sequenced at a later time point when he relapsed, this resequencing was done by WGS. Therefore there are 11 patients, one of which with two samples, all of which were sequenced with matched normal controls, amounting to a total number of 24 NGS samples.	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	24
EGAD00001005061	Bam files for 124 samples (62 tumor vs blood pairs); Whole Genome Sequencing performed on Illumina HiSeq X Ten	HiSeq X Ten	124
EGAD00001005069	Whole genome and transcriptome sequencing of a pancreatic tumor harboring a RASGRP1 gene fusion	HiSeq X Ten Illumina HiSeq 4000	2
EGAD00001005113	50 samples of 16 individuals with Gastrointestinal Tumor. Patients were sequenced in various combinations of WGS, Exome and RNA sequencing.	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	50
EGAD00001005249	Exome and RNA sequencing data for EGAS00001003776 - one female patient with neurofibroma/schwannoma hybrid nerve sheath tumor (N/S HNST)	Illumina HiSeq 2500	2
EGAD00001005492	Content: 60 GB patient tumours and 4 normal brain samples combined in pairs by region (x2=8 total input samples). RNAseq: 1 lane per sample, total strand-specific rRNA-depleted (normal samples were combined = 2 lanes/samples per brain region). WGBS: 2 lanes per sample (normal samples were combined = 2 lanes/samples per brain region). ChIPseq (histone mark): a subset of 20 GB samples were profiled. For the same modification were multiplexed and sequenced on 4 lanes each (H3K27ac, H3K4me1) or a single lane (all others). WGS: used as matching input control for the 20 ChIPseq samples. Data type and technology: RNA-seq: PE 100bp sequenced on HiSeq2000. WGBS: PE 100bp sequenced on HiSeq2000/4000. ChIPseq: SE 50bp sequenced on HiSeq2000/4000. WGS: PE 150bp sequenced on HiSeq X.		172
EGAD00001005493	Content: 2 GB RTK I cell lines (LN229, ZH487) in two conditions (NT control and shSOX10). RNAseq: single replicates per condition, polyA+ RNA sequencing, SE. ATACseq: biological replicates per condition, SE. ChIPseq (histone H3 modifications, LN229 only): all marks for each condition were pooled and sequenced on two lanes for each pool. ChIPseq (BRD4 and SOX10): SOX10 libraries were sequenced on single lanes. BRD4 samples were multiplexed and sequenced in two lanes. ChIPseq input samples are also included. Data type and technology: RNAseq: SE 50bp sequenced on HiSeq2000/4000. ATACseq: SE 50bp sequenced on HiSeq2000/4000. ChIPseq: SE 50bp sequenced on HiSeq2000/4000.		6
EGAD00001005938	This dataset contains 3 pairs of exomes, germline (from whole blood) and patient-derived xenograft (PDX), from human pancreatic durctal adenocarcinoma patients. The data is referred to in the publication: "Pro-immunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy" (Nature Communications, 2020) Abstract: Cancer types with lower mutational load and a non-permissive tumor microenvironment are intrinsically resistant to immune checkpoint blockade. While the combination of cytostatic drugs and immunostimulatory antibodies constitutes an attractive concept for overcoming this refractoriness, suppression of immune cell function by cytostatic drugs may limit therapeutic efficacy. Here we show that targeted inhibition of mitogen-activated protein kinase (MAPK) kinase (MEK) does not impair dendritic cell-mediated T-cell priming and activation. Accordingly, combining MEK inhibitors (MEKi) with agonist antibodies (Abs) targeting the immunostimulatory CD40 receptor resulted in potent synergistic anti-tumor efficacy. Detailed analysis of the mechanism of action of MEKi GDC-0623 by means of flow cytometric analysis of the tumor immune infiltrate and whole tumor transcriptomics showed that, in addition to its cytostatic impact on tumor cells, this drug exerts multiple pro-immunogenic effects, including the suppression of M2-type macrophages, myeloid derived suppressor cells and CD4+ T-regulatory cells. In addition, MEKi was found to induce tumor-cell intrinsic interferon signaling, which contributed to antigen presentation by tumor cells. Finally, the tumoridical impact of MEKi involves the activation of multiple pro-inflammatory pathways involved in immune cell effector function in the tumor microenvironment. Our data therefore indicate that the combination of MEK inhibition with agonist anti-CD40 Ab is a promising therapeutic concept, especially for the treatment of mutant Kras-driven tumors such as pancreatic ductal adenocarcinoma.	Illumina HiSeq 2500	6
EGAD00001005965	Single-cell ATAC-seq data for 5 CLL samples (2 controls, 3 tumor) of the CancerEpiSys-PRECiSe project.	Illumina HiSeq 2000	5
EGAD00001005966	Tagged-WGBS for 3 Naive B Cell samples of the CancerEpiSys-PRECiSe project.	Illumina HiSeq 2000	3
EGAD00001005967	ATAC-seq data for 26 CLL samples (7 controls, 19 tumor) of the CancerEpiSys-PRECiSe project.	Illumina HiSeq 2000 Illumina HiSeq 4000	26
EGAD00001005968	long RNA data for 27 CLL samples (8 controls, 19 tumor) of the CancerEpiSys-PRECiSe project.	Illumina HiSeq 2000	27
EGAD00001005969	ChIPseq data for 31 CLL samples (12 controls, 19 tumor) of the CancerEpiSys-PRECiSe project; containing histone H3, histone modifications and transcription factor binding sites (CTCF, EBF1).	Illumina HiSeq 2000 NextSeq 550	31
EGAD00001005970	WGBS data for 75 paired fastq, spread over 31 samples (4 healthy T-cell, 7 healthy B-cell, 20 B-cell CLL tumors) of the CancerEpiSys-PRECiSe project.	Illumina HiSeq 2000	31
EGAD00001006005	liver cancer paired with normal controls, viral and non-viral origin		108
EGAD00001006014	None	HiSeq X Ten Illumina HiSeq 4000	2
EGAD00001006016	None	HiSeq X Ten Illumina HiSeq 2000	12
EGAD00001006023	None	HiSeq X Ten Illumina HiSeq 4000	2
EGAD00001006057	paired WGS sequencing of nodal B-cell lymphoma, one tumor and one control, one patient (H021). Sequencing on Hiseq XTen with TruSeq Nano library preparation kit.	HiSeq X Ten	2
EGAD00001006058	paired WGS data of one tumor of one patient with nodal B-cell lymphoma. Tumor cells were sorted according to CD48 expression in a high and low fraction. Library preparation with TruSeq Nano and sequencing on Hiseq XTen.	HiSeq X Ten	2
EGAD00001006059	Tumors and control of nodal B-cell lymphoma of one patient. WES sequencing on Illumina HiSeq 4000 with Agilent SureSelect V5+UTRs. Bam files were aligned with bwa mem to hg19.	Illumina HiSeq 4000	5
EGAD00001006060	paired EXOME sequencing on Illumina HiSeq 4000 using Agilent SureSelect V6 of one tumor sample of one patient with B-cell lymphoma. The bam-file was mapped to the hg19 genome.	Illumina HiSeq 4000	1
EGAD00001006184	linking MASTER H021-Cohort to EGAS0001004157	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	10
EGAD00001006189	Paired WGS and RNA-Seq data of patients with multiple myeloma (MM) refractory to immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs). We performed whole genome and transcriptome sequencing of 39 heavily pretreated RRMM patients with at least double refractoriness revealing complex structural changes and a high mutational load.	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 4000	116
EGAD00001006243	None	HiSeq X Ten	2
EGAD00001006263	linking 3 samples out of EGAD00001002528 to EGAS0001004517	Illumina HiSeq 2000	3
EGAD00001006264	18 samples of RNA-Seq of serially passaged TIC-enriched spheres of colorectal cancer (CRC), sequenced on HiSeq2000 and HiSeq2500	Illumina HiSeq 2500	8
EGAD00001006265	WGS data of serially passaged TIC-enriched spheres of colorectal cancer	HiSeq X Ten	6
EGAD00001006266	WES data of serially passaged TIC-enriched spheres of colorectal cancer (CRC)	Illumina HiSeq 2000 Illumina HiSeq 2500	15
EGAD00001006297	270 samples with ALK-positiv non-small cell lung cancer, targeted sequencing (198 kb panel size)		270
EGAD00001006298	268 samples with ALK-positiv non-small cell lung cancer, ultra-low coverage whole genome sequencing		268
EGAD00001006336	Paired whole exome sequencing data of the HIPO head and neck cancer (HNC) (n=83), using Agilent SureSelect V4+UTRs and V6+UTRs with the sequencing platforms HiSeq2000 and HiSeq2500. The reads were aligned to hg19. This is part of project H019.		166
EGAD00001006538	WGBS data for EGAS00001004660, "Aggressive PDACs show hypomethylation of repetitive elements and the execution of an intrinsic IFN program linked to a ductal cell-of-origin"		13
EGAD00001006539	RNA data for EGAS00001004660, "Aggressive PDACs show hypomethylation of repetitive elements and the execution of an intrinsic IFN program linked to a ductal cell-of-origin"		23
EGAD00001006544	ATAC-seq data for 2 glioblastoma cell lines (LN229, ZH487), NT and SOX10KD.		2
EGAD00001006545	Whole genome sequencing data for 20 human glioblastoma patients.		20
EGAD00001006546	Whole Genome Bisulfite data for human glioblastoma patients, EGAS00001003953. 68 human samples		68
EGAD00001006547	RNA data for human glioblastoma patients, EGAS00001003953. 64 human samples, 2 cell lines (LN229, ZH487).		66
EGAD00001006548	ChIPseq data for human glioblastoma patients, EGAS00001003953. Mix of input, H3K27ac, H3K27me1, H3K27me3, H3K36me3, H3K4me1, H3K4me3, H3K9me3 and BRD, 20 human samples, 2 cell lines (LN229, ZH487).		22
EGAD00001006613	linking 82 samples/82 runs of WES from EGAS00001004338 Umbrella study to EGAS0001004786 study	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	-
EGAD00001006614	linking 58 samples/58 runs of WGS from EGAS00001004338 Umbrella study to EGAS0001004786 study	HiSeq X Ten	-
EGAD00001006615	linking 55 samples/74 RNA-Seq runs - out of EGAS00001004338 Umbrella study to EGAS0001004786	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	-
EGAD00001006739	None	HiSeq X Ten	17
EGAD00001006785	None	Illumina HiSeq 4000	9
EGAD00001006903	This dataset includes 87 scRNA-seq samples of bone marrow aspirates of 20 relapsed/refractory patients generated with the 3´(v2) kit of the 10x Chromium platform. Bone marrow cells have been sorted using CD138 +/- fractions using magnetic beads for plasma cell enrichment and processed independently. For 14/20 patients multiple treatment timepoints are available that includes samples before treatment and at relapse during treatment.	Illumina HiSeq 4000	87
EGAD00001007563	We analyzed chromothripsis in 252 human breast cancers from two patient cohorts (149 metastatic breast cancers, 63 untreated primary tumors, 29 local relapses, 11 longitudinal pairs) using whole-genome and whole-exome (paired) sequencing. A lot of the WGS samples were sequenced on Illumina HiSeq X-Ten using Illumina TruSeq Nano DNA. For exome sequencing Agilent_SureSelect_V5+UTRs has been used (sequencing on Hiseq2000, Hiseq2500 and Hiseq4000). For exome sequencing Agilent_SureSelect_V5+UTRs has been used (sequencing on Hiseq2000, Hiseq2500 and Hiseq4000).	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	516
EGAD00001007713	Paired fastq files ( 12 pairs, WES) of EGFR treated and untreated PDX models of mCRCs of 2 patiens sequenced on Illumina HiSeq 2000, the enrichment kit was Agilent SureSelect V5+UTRs.	Illumina HiSeq 2000	6
EGAD00001007817	This dataset contains 538 Tumor and Control WGS and WES files for samples already submitted and published in study EGAS00001004276	Illumina HiSeq 4000 NextSeq 500	400
EGAD00001007818	Some data was previously submitted data under study number EGAS00001004276. In this new dataset we provide additional WGS and Avenio Surveillance Panel data. We utilized 43 ALK+ NSCLC patients receiving targeted ALK therapy to evaluate ctDNA levels based on matched panel-based targeted next generation sequencing (tNGS) and untargeted shallow whole genome sequencing (sWGS). For the Avenio panel the sequencing was done on Illumina NextSeq 550 paired end 150 bp, for WGS the sequencing was done on Illumina HiSeq 4000, partly with KAPA_Hyper_Prep_Kit. In this dataset there are 132 WGS tumor samples and 134 panel sequencing data of plasma.	Illumina HiSeq 4000 NextSeq 550	266
EGAD00001008150	Four PAIRED WGS samples, tumor and control, were sequenced on a HiSeq X Ten and the library preparation kit used was Illumina TruSeq Nano DNA. The tumor was multiple myeloma from bone marrow.	HiSeq X Ten	4
EGAD00001008363	two tables containing RNASeq expression values to patients with RNA-Seq data in the study "Comprehensive genomic characterization of refractory multiple myeloma (HIPO_067)". From the bam files gene expression was calculated with the annotation of Gencode.v19. Raw Counts and TPM values are given in one table, the other contains filtered TMM normalized CPM values (genes < 1CPM omitted).		-
EGAD00001008618	Whole genome paired sequencing of Multiple Myeloma CD138positive bone marrow plasma cells and saliva control samples (6 tripletts, tumor1, tumor2, saliva control) from 6 patients. WGS was done on HiSeq X-Ten or Novaseq 6000 with Illumina TruSeq Nano DNA.	HiSeq X Ten Illumina NovaSeq 6000	18
EGAD00001008619	RNA-Seq data on multiple myeloma CD138positive bone marrow plasma cells, 11 samples, sequenced on HiSeq 4000 and HiSeq X-Ten, using mostly the TruSeq stranded mRNA Kit.	HiSeq X Ten Illumina HiSeq 4000	11
EGAD00001008638	FPKM expression values of the CUP/reference/validation cohort used for tissue-of-origin prediction based on transcriptomic data		-
EGAD00001008669	Beta values of methylation data of the CUP/reference/validation cohort (H021) used for the validation cohort described in the publication		1
EGAD00001008844	Rare cancer sequencing data of 23 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	16
EGAD00001008845	Rare cancer sequencing data of 28 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	22
EGAD00001008846	Rare cancer sequencing data of 45 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	26
EGAD00001008847	Rare cancer sequencing data of 95 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	64
EGAD00001008848	Rare cancer sequencing data of 55 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	44
EGAD00001008849	Rare cancer sequencing data of 87 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	58
EGAD00001008850	Rare cancer sequencing data of 59 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	38
EGAD00001008851	Rare cancer sequencing data of 75 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	49
EGAD00001008852	Rare cancer sequencing data of 50 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	34
EGAD00001008853	Rare cancer sequencing data of 44 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	30
EGAD00001008854	Rare cancer sequencing data of 40 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	26
EGAD00001008855	Rare cancer sequencing data of 97 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	61
EGAD00001008856	Rare cancer sequencing data of 48 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	33
EGAD00001008857	Rare cancer sequencing data of 58 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	40
EGAD00001008858	Rare cancer sequencing data of 49 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	35
EGAD00001008859	Rare cancer sequencing data of 243 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	164
EGAD00001008860	Rare cancer sequencing data of 47 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	41
EGAD00001008861	Rare cancer sequencing data of 92 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	62
EGAD00001008862	Rare cancer sequencing data of 145 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	104
EGAD00001008863	Rare cancer sequencing data of 119 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	76
EGAD00001008865	Rare cancer sequencing data of 87 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2500 Illumina HiSeq 4000	87
EGAD00001008866	Rare cancer sequencing data of 48 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	48
EGAD00001008867	Rare cancer sequencing data of 12 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	12
EGAD00001008868	Rare cancer sequencing data of 94 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	91
EGAD00001008869	Rare cancer sequencing data of 46 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	46
EGAD00001008870	Rare cancer sequencing data of 62 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	59
EGAD00001008871	Rare cancer sequencing data of 119 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	117
EGAD00001008872	Rare cancer sequencing data of 54 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	52
EGAD00001008873	Rare cancer sequencing data of 30 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2500 Illumina HiSeq 4000	30
EGAD00001008874	Rare cancer sequencing data of 18 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	18
EGAD00001008875	Rare cancer sequencing data of 64 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2500 Illumina HiSeq 4000	61
EGAD00001008876	Rare cancer sequencing data of 18 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	12
EGAD00001008877	Rare cancer sequencing data of 55 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	55
EGAD00001008878	Rare cancer sequencing data of 38 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	31
EGAD00001008879	Rare cancer sequencing data of 56 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	54
EGAD00001008880	Rare cancer sequencing data of 86 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2500 Illumina HiSeq 4000	83
EGAD00001008881	Rare cancer sequencing data of 49 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	44
EGAD00001008882	Rare cancer sequencing data of 91 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	78
EGAD00001008883	Rare cancer sequencing data of 162 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2500 Illumina HiSeq 4000	149
EGAD00001008884	Rare cancer sequencing data of 83 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	71
EGAD00001008885	Rare cancer sequencing data of 96 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	89
EGAD00001008886	Rare cancer sequencing data of 29 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	28
EGAD00001008887	Rare cancer sequencing data of 66 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	58
EGAD00001008888	Rare cancer sequencing data of 48 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	41
EGAD00001008889	Rare cancer sequencing data of 22 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	17
EGAD00001008890	Rare cancer sequencing data of 76 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	72
EGAD00001008891	Rare cancer sequencing data of 164 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	159
EGAD00001008892	Rare cancer sequencing data of 42 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	42
EGAD00001008893	Rare cancer sequencing data of 112 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	100
EGAD00001008894	Rare cancer sequencing data of 34 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	28
EGAD00001008895	Rare cancer sequencing data of 49 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	43
EGAD00001008896	Rare cancer sequencing data of 137 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	138
EGAD00001008897	Rare cancer sequencing data of 246 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	250
EGAD00001008898	Rare cancer sequencing data of 34 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2500 Illumina HiSeq 4000	34
EGAD00001008899	Rare cancer sequencing data of 6 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	6
EGAD00001008900	Rare cancer sequencing data of 142 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	134
EGAD00001008901	Rare cancer sequencing data of 28 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 4000	24
EGAD00001008902	Rare cancer sequencing data of 85 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	77
EGAD00001008903	Rare cancer sequencing data of 36 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	34
EGAD00001008904	Rare cancer sequencing data of 112 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	106
EGAD00001008905	RNA-Seq, WES and WGS data of 5 rare tumor/control pairs which were submitted to other HIPO projects, not MASTER. The sequencing was always paired.	HiSeq X Ten Illumina HiSeq 2000	11
EGAD00001008906	Part of the published data from EGAS00001004662 resulted in the publication of this study EGAS00001004813	HiSeq X Ten	5
EGAD00001008969	Reads were processed with the RNA-seq workflow 1.3.0 developed by the DKFZ Omics IT and Data Management Core Facility (https://github.com/DKFZ-ODCF/RNAseqWorkflow). First, FASTQ reads were aligned via two-pass alignment using STAR 2.5.3a. The STAR index was generated from the 1000 Genomes assembly and GENCODE Version 19 gene models with a sjdbOverhang of 200. Duplicate marking of the resultant main alignment file was done with sambamba 0.6.5. Gene-specific read counting was performed using featureCounts (from Subread 1.5.1) over exon features based on GENCODE Version 19 gene models. Both reads of a paired fragment were used for counting, and the quality threshold was set to 255, indicating that STAR found a unique alignment. Strand-specific counting was also used. For RPKM and TPM calculations, all genes on chromosomes X and Y, the mitochondrial genome, as well as rRNA and tRNA genes were omitted as they are likely to introduce library size estimation biases.		10
EGAD00001008970	Nanopore RNA Sequencing was done for 10 tumor samples. Direct cDNA sequencing was performed using the SQK-DCS109 kit (Oxford Nanopore Technologies). For analysis of a single sample on a MinION flow cell (version R9.4.1), 5 μg RNA was used as input. For multiplexing on a MinION flow cell, 2.5 μg RNA per sample was used as input, and the native barcoding expansion kit EXP-NBD104 was employed in conjunction with SQK-DCS109. After reverse transcription with Maxima H Minus Reverse Transcriptase (Thermo Scientific), second-strand synthesis was performed using the 2x LongAmp Taq Master Mix (New England Biolabs). The resulting double-stranded cDNA was subjected to end-repair and dA-tailing using the NEBNext Ultra End Repair/dA-Tailing Module (New England Biolabs). For multiplexed libraries, this step was followed by barcode ligation and library pooling. Next, libraries were quantified with a Qubit Fluorometer 3.0 (Life Technologies). Finally, sequencing adapters were added to the library preparations and ligated with Blunt/TA Ligase Master Mix (New England Biolabs), followed by further quality control using a Qubit. Samples ACC1 and ACC2 were analyzed on individual MinION flow cells, while the remaining eight samples were sequenced as multiplexed libraries on two MinION flow cells by pooling four samples for each run. Five ACC samples were also analyzed individually on Flongle flow cells	MinION	10
EGAD00001008971	Fastq files of paired RNA-Seq of 10 different tumor samples, for which Nanopore and Illumina sequencing was compared. Illumina sequencing was carried out with HiSeq4000 or HiSeq X-Ten using the Illumina TruSeq stranded mRNA Kit.	HiSeq X Ten Illumina HiSeq 4000	10
EGAD00001009270	10X Genomics scRNA- and TCR-sequencing (Chromium Next GEM Single Cell 5’ Reagent Kit v1.1) was performed on the plasma cell depleted mononuclear fraction of bone marrow aspirates from 6 patients with newly diagnosed multiple myeloma. Generated gene expression libraries were paired-end sequenced on the NovaSeq 6000 S2. Generated V(D)J libraries were paired-end sequenced on the NextSeq 550.	Illumina NovaSeq 6000 NextSeq 550	-
EGAD00001009272	WES/WGS sequencing data of 234 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	233
EGAD00001009273	WES/WGS sequencing data of 86 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	86
EGAD00001009274	WES/WGS sequencing data of 337 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten Illumina HiSeq 4000	319
EGAD00001009275	WES/WGS sequencing data of 56 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	56
EGAD00001009276	WES/WGS sequencing data of 75 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	74
EGAD00001009277	WES/WGS sequencing data of 44 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	40
EGAD00001009278	WES/WGS sequencing data of 242 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired	Illumina HiSeq 2500 Illumina HiSeq 4000	242
EGAD00001009279	WES/WGS sequencing data of 239 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired	HiSeq X Ten	218
EGAD00001009490	Oxford Nanopore Technologies (ONT) long-read sequencing in a paired diagnostic and post- therapy medulloblastoma (2 samples). One sequencing was done on GridION, the other one on a P2 Solo. In both cases the SQK LSK-109 Kit was used for preparation.	GridION PromethION	2
EGAD00001009624	high coverage whole genome sequencing of 38 samples was done on a patterned flowcell v.2.5 (150 bp paired end, HiSeq X Ten) with coverage of about 60x for the tumor and whole blood control samples. All tumors had a tumor cell content of ≥60%. Sequencing libraries were prepared using the Truseq DNA Nano kit (Illumina) according to the manufacturers’ instructions and size selected using SPRI beads (Beckman Coulter Genomics).	HiSeq X Ten	18
EGAD00001009627	For WGS DNA of tumor or control samples was prepared for paired sequencing using the Illumina TruSeq DNA Nano Kit and sequenced on NovaSeq 6000. For RNA-Seq the sequencing Kit Illumina TruSeq stranded mRNA was used with the same sequencer. There are 4 samples for WGS (18 runs) and 4 samples for RNA (4 runs) available.	Illumina NovaSeq 6000	10
EGAD00001009670	Sequencing data of 20 tumor runs (different tumors), which were uploaded to EGAS00001004813 and used in the ImmuNeo publication. The sequencing was always paired and run on Illumina HiSeq sequencers.	HiSeq X Ten Illumina HiSeq 4000	1
EGAD00001009671	Sequencing data of 39 tumor and control runs (different tumors and blood controls), which were uploaded to EGAS00001004813 and reused in this ImmuNEO publication. The sequencing was always paired.	HiSeq X Ten Illumina HiSeq 4000	-
EGAD00001009679	subset of 11 samples (RNA-Seq and WGS) from study EGAS00001005973, which was published earlier and are linked here to study EGAS00001006538	HiSeq X Ten Illumina HiSeq 4000	1
EGAD00001009680	Paired RNA sequencing of 30 samples RRMM using Illumina TruSeq stranded mRNA kit and either HiSeq2000 or HiSeq X Ten for sequencing.	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 4000	30
EGAD00001009681	Paired scRNA sequencing using 10xgenomics library preparation and Illumina HiSeq4000 for sequencing of 2 samples RRMM (relapsed refractory multiple myeloma)	Illumina HiSeq 4000	2
EGAD00001009682	Here is mostly paired WGS data of RRMM, 45 samples (tumors and controls) in 86 runs. This data was produced by using Illumina TruSeq Nano DNA and NovaSeq6000 or HiSeq X Ten for sequencing. One tumor/control pair is WES data using Agilent SureSelect V5+UTRs and NovaSeq6000 for sequencing.	HiSeq X Ten Illumina NovaSeq 6000	45
EGAD00001009683	scATAC sequencing was performed of 29 samples of RRMM tumors using 10xGenomics for the preparation and NovaSeq6000 for sequencing.	Illumina NovaSeq 6000	29
EGAD00001009689	FAST5 original nanopore data from MinION sequencing of 10 tumor samples		10
EGAD00001009690	Reads were aligned to 1000 Genomes assembly reference (hs37d5) using minimap2 2.22. SAM-to-BAM conversion, BAM sorting and indexing were performed with SAMtools 1.13. Read summarization was performed with featureCounts (from Subread 2.0.3) over exon features based on GENCODE Version 19 gene models. Strand specific counting was used.		10
EGAD00001009705	Paired Exome sequencing of 34 samples (tumors and controls) of different tumors. The samples were prepared using Agilent SureSelect V5+UTRs, the sequencing was done on Illumina HiSeq 4000.	Illumina HiSeq 4000	34
EGAD00001009706	Paired RNA sequencing data (21 runs/ 17 samples) of different tumors. The samples were prepared using the Illumina TruSeq stranded mRNA Kit. The sequencing was done on Illumina HiSeq 4000.	Illumina HiSeq 4000	17
EGAD00001009730	Paired RNA-Seq of four patients with advanced Parathyroid carcinoma (PC). The library was prepared using the Illumina TruSeq stranded mRNA Kit, the sequencing was done either on an Illumina HiSeq 4000 or on Illumina NovaSeq 6000.	Illumina HiSeq 4000 Illumina NovaSeq 6000	4
EGAD00001009731	Paired WGS data of four patients with advanced Parathyroid carcinoma (PC). There are tumor/control pairs (buffy coat control). The library was prepared with Illumina TruSeq Nano DNA, the sequencing was done with HiSeq X Ten.	HiSeq X Ten	8
EGAD00001010046	WES/WGS sequencing data of 37 germline runs, which were uploaded to umbrella studies. The sequencing was always paired. The WGS sequencing was on HiSeq X Ten using the Illumina TruSeq DNA Nano Kit. The WES Sequencing was on HiSeq4000 with Agilent Sureselect V5+UTR.	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000	1
EGAD00001010047	The control samples (mostly blood) of 351 samples (paired WGS and WES sequencing) are in this dataset. The WGS was in nearly all cases at an Illumina HighSeq X Ten with the Illumina TruSeq Nano DNA Kit. The WES mostly on Illumina HighSeq 4000 with the Agilent SureSelect V5 plus UTRs Kit.	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000 Illumina NovaSeq 6000	353
EGAD00001010108	Whole genome, exome and RNA sequencing of TFCP2-rearranged rhabdomyosarcoma, 86 samples of paired fastq files, sequenced on: Illumina HiSeq 2500 using Agilent SureSelect WGS, Illumina HiSeq 2500 using Illumina TruSeq RNA, Illumina HiSeq 2500 using Agilent SureSelect v5 WES (+UTRs), Illumina HiSeq 4000 using Agilent SureSelect WGS, Illumina HiSeq 4000 using Illumina TruSeq stranded mRNA Kit, Illumina HiSeq 4000 using Agilent SureSelect v5 WES stranded mRNA Kit, Illumina NovaSeq 6000 using Illumina TruSeq Stranded mRNA, Illumina NovaSeq 6000 using Illumina TruSeq Nano DNA, Illumina HiSeq X Ten using TruSeq Nano DNA.	HiSeq X Ten Illumina HiSeq 2500 Illumina HiSeq 4000 Illumina NovaSeq 6000	50
EGAD00001010257	Sequencing data of 77 sarcoma tumor and control runs, which were uploaded to EGAS00001004813. The sequencing was always paired.	HiSeq X Ten	1
EGAD00001010258	Sequencing data of 144 sarcoma tumor and control runs, which were uploaded to EGAS00001004813. The sequencing was always paired.	Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	1
EGAD00001010276	Sequencing data of 410 sarcoma tumor runs, which were uploaded to EGAS00001004813. The sequencing was always paired.	HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 Illumina HiSeq 4000	1
EGAD00001010277	Paired WGS samples (tumor and control) of one Sarcoma case. The paired sequencing was done on Hiseq X Ten with Illlumina TruSeq Nano DNA.	HiSeq X Ten	2
EGAD00001010278	Paired Exome sequencing of Sarcoma tumor and control of 10 samples (5 tumor/control pairs). The sequencing was done on Illumina Hiseq 4000 and Agilent Sureselect V5+UTRs kit.	Illumina HiSeq 4000	10
EGAD00001010884	Paired RNA-Seq of 32 samples of chemo-naïve and post-chemotherapy PDAC tumors (HIPO_015) to define the molecular and cellular impact of neoadjuvant chemotherapy. Transcriptome analysis combined with high resolution mapping of whole tissue sections identified GATA6 (Classical), KRT17 (Basal-like) and Cytochrome P450 3A (CYP3A) co-expressing cells that were preferentially enriched in post-CTX resected samples. The sequencing was done on HiSeq2000/HiSeq2500 using the Takara_SMARTer_Ultra_Low_Input_RNA_and_NEBNext_ChIP-Seq Kit.	Illumina HiSeq 2000 Illumina HiSeq 2500	32
EGAD00010000947	Lymphoma samples using CytoSNP	Illumina CytoSNP	35
EGAD00010000948	Lymphoma samples using 450k	Illumina 450k	95
EGAD00010000949	Lymphoma samples using HumanOmni	Illumina HumanOmni2.5	104
EGAD00010001642		Illumina EPIC methylation bead array	25
EGAD00010001643		Illumina 450k methylation bead array	73
EGAD00010001797	Methylation microarray profiling (Illumina Human Methylation 450k and EPIC platforms) of 60 adult glioblastomas. Tumours were subtyped using the approach from Sturm et al. (https://doi.org/10.1016/j.ccr.2012.08.024): 12 IDH, 18 MES, 12 RTK I, 18 RTK II. DNA was prepared, assayed on the microarrays, and raw data computationally processed as described in Capper et al., "DNA methylation-based classification of central nervous system tumours": https://www.nature.com/articles/nature26000		60
EGAD00010001936	Gene expression of 12 colon cancer TSCs (sensitive or resistant) after 12h treatment with 3ÂµM NCT02 or DMSO (control) was analyzed using Illumina microarrays (HumanHT-12 v4 BeadChip).	oligonucleotide beads of HumanHT-12 V4 R2 Expression BeadChips (Illumina)	24
EGAD00010002004	PDAC primary cell lines methylation		7
EGAD00010002005	PDAC PDX methylation		18
EGAD00010002036	CUP samples using 850k	Illumina 850k	55
EGAD00010002355	Methylation microarray data (Illumina 850K) of 52 thymic epithelial tumors. 13 patients with thymoma A and B, 32 thymic carcinoma (TC) and 7 neuroendocrine tumors of the thymus (NET).	Illumina 850k	52
EGAD00010002451	Methylation profiling of 345 sarcoma and TFCP2-rearranged rhadomyosarcoma samples, using the approach described "Genomic, transcriptomic, functional, and mechanistic characterization of rhabdomyosarcoma with FUS-TFCP2 or EWSR1-TFCP2 fusions"	Infinium Methylation EPIC BeadChip	345